Amarin Corp Plc (AMRN)

[rafunrafun]

Is this of any importance to us?

"TP-252 is a novel, mineral amino acid-based derivative of eicosapentaenoic acid (EPA) that delivers high plasma levels of EPA free fatty acid (EPA-FFA). Clinical proof-of-concept demonstrating that EPA-FFA reduces polyp burden in FAP patients has been reported in a Phase II/III randomized, double-blind, placebo-controlled trial completed in 2008 (West et. al. Gut 2010; 59:918-25). Thetis expects to begin clinical trials in 2017 to study TP-252 as adjunct therapy to endoscopic surveillance for the treatment of young FAP patients."

http://thetispharma.com/thetis-receives-orphan-drug-designation-for-tp-252-in-familial-adenomatous-polyposis/

This just came out yesterday.